BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema

If approved, ORLADEYO would be the first oral, once-daily therapy in the European Union to treat patients with HAE by preventing recurrent attacks.